AbbVie (NYSE:ABBV) : Average target price received by AbbVie (NYSE:ABBV) is $71.77 with an expected standard deviation of $10.83. The most aggressive target on the stock is $90, whereas the most downbeat target is $47. 13 financial analysts are currently covering the stock.
Shares of AbbVie Inc. appreciated by 0.98% during the last five trading days but lost 1.46% on a 4-week basis. AbbVie Inc. is up 8.86% in the last 3-month period. Year-to-Date the stock performance stands at 6.62%. Also, Equity Analysts at the Brokerage Firm, BMO Capital, downgrades their rating on the shares of AbbVie (NYSE:ABBV). BMO Capital has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on June 10, 2016.
AbbVie (NYSE:ABBV) has an average broker rating of 2.14, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 7 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
AbbVie (NYSE:ABBV): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $61.79 and $61.14 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $62.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $61.91, notching a gain of 0.16% for the day. The total traded volume was 7,920,605 . The stock had closed at $61.81 on the previous day.
In an insider trading activity, Gonzalez Richard A, director officer (Chairman of the Board and CEO) of Abbvie Inc., unloaded 285,953 shares at an average price of $63.87 on June 2, 2016. The total amount of the transaction was worth $18,263,818, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.